Your session is about to expire
← Back to Search
Domvanalimab + Zimberelimab for Cancer
Study Summary
This trial is testing a new cancer drug to see if it is safe and works well.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had active cancer in the past year, except for certain curable types.I have a recent biopsy or tissue sample taken within the last 6 months.I have not received any live vaccines in the last 4 weeks.I have at least one tumor that can be measured and it's not in an area treated with radiation.My organs and bone marrow are working well.My cancer has no standard treatment available.I am fully active or can carry out light work.I do not have an active autoimmune disease or a history that required strong immune system medications, except for vitiligo or childhood asthma.I am able to understand and sign the consent form.I haven't had cancer treatment or fully recovered from its side effects in the last 4 weeks.I am 18 years old or older.I do not have any health conditions that would make taking new medications dangerous.I had major surgery with general anesthesia over 4 weeks ago.I stopped taking high doses of steroids or similar medicines more than 2 weeks ago.
- Group 1: Domvanalimab and Zimberelimab Q6W combination therapy
- Group 2: Domvanalimab + zimberelimab Q3W Combination Therapy
- Group 3: Domvanalimab Monotherapy
- Group 4: Domvanalimab + zimberelimab Q2W Combination Therapy
- Group 5: Domvanalimab + zimberelimab Q4W Combination Therapy
- Group 6: Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Domvanalimab been given regulatory approval by the FDA?
"Having only limited evidence for safety and efficacy, domvanalimab was judged to be a 1 on the scale of risk assessment."
Are there numerous establishments currently conducting this experiment within the United States?
"The Angeles Clinic and Research Institute in Los Angeles, California, Carolina BioOncology Institute in Huntersville, North carolina, Medical Oncology Associates (also known as Summit Cancer Centers) located in Spokane Washington are enrolling subjects for this clinical study. Additionally 4 other sites across the country will serve to recruit participants."
Is recruitment for this research project still ongoing?
"According to clinicaltrials.gov, the recruitment period for this medical trial has closed; it was initially published on September 12th 2018 and last updated October 17th 2022. However, there are currently 2383 other trials actively recruiting participants."
Share this study with friends
Copy Link
Messenger